Sparrow Pharmaceuticals is developing drugs for co-administration with corticosteroids to mitigate dose-limiting side effects.
Corticosteroid Co-Administration-Corticosteroids are useful for the treatment of a wide range of autoimmune and inflammatory conditions, as well as certain cancers. The utility of these drugs is limited by serious side effects such as metabolic dysfunction, fat redistribution to the liver, blindness, depression and psychosis. Sparrow Pharmaceuticals is developing proprietary compounds that can be co-administered with corticosteroids and mitigate these side effects. The goal is to allow for increased corticosteroid dosing, therapeutic duration, and usage by at risk patients. The drugs work by limiting distribution of the steroids to side-effect prone tissues such as the liver and eyes.
Sparrow Pharmaceuticals Secures License From Astellas to Develop Alternative Treatment for Autoimmune and Inflammatory Conditions
“Biological” Sept 25, 2018, John Conrad
Phase I: Oral administration (work by Astellas before licensing)
Pre-Clinical: Other administration routes (inhaled, injected, intravenous, ophthalmic, topical)
- Autoimmune diseases
- Small molecules
Sparrow Pharmaceuticals is interested in academic and industry partnerships to support the pre-clinical development of alternative delivery routes for its lead small molecules.